Abviris Deutschland GmbH

📍 Ahrensburg, Germany🗓 Founded 2014👥 4 employees💰 Last funded Dec 2015
Biotechnology Research🌐 abviris.com
Website LinkedIn
Moving from cell to blood based HPV cancer screening, Abviris has developed a new patented generation of Immune Oncology Diagnostics for the early detection of HPV induced cancer, allowing a blood based entire body screen within minutes by using just one drop of blood. Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer. Our patented diagnostics provide a key contribution to a favourable prognosis, such as early tumour detection and enhanced post-therapy patient management. As pioneers in HPV serology, we develop highly innovative solutions, including the Prevo-Check®, the world´s first entire-body screening test for HPV16-induced cancer, which delivers results within minutes using just a single drop of blood.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Abviris Deutschland GmbH?
Abviris Deutschland GmbH has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Abviris Deutschland GmbH last raise funding?
The most recent investment in Abviris Deutschland GmbH recorded on gritt.io was in December 2015.
When was Abviris Deutschland GmbH founded?
Abviris Deutschland GmbH was founded in 2014.
What industry is Abviris Deutschland GmbH in?
Abviris Deutschland GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Abviris Deutschland GmbH based?
Abviris Deutschland GmbH is headquartered in Ahrensburg, Germany.